Clinical Trial: Study Of Continuous Use Of Celecoxib Vs. Intermittent Use

This study is currently recruiting patients.
Verified by Pfizer August 2005

Sponsored by: Pfizer
Information provided by: Pfizer Identifier: NCT00139776


To determine whether continuous use of celecoxib over a 6 month period is more effective than intermittent use in preventing spontaneous osteoarthritis flares.
Condition Intervention Phase
 Drug: Celecoxib
Phase IV

MedlinePlus related topics:  Osteoarthritis

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: Study Of Efficacy And Safety Of Continuous Use Of Celecoxib Vs. Usual Use Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee

Further Study Details: 
Primary Outcomes: To determine whether continuous use over a 6-month period of celecoxib 200 mg per day is more effective than intermittent use of celecoxib 200 mg per day in preventing spontaneous osteoarthritis flares.
Secondary Outcomes: To evaluate the safety and tolerability of continuous use over a 6-month period of celecoxib 200 mg QD versus "usual use" celecoxib 200mg QD. To assess whether disease management
Expected Total Enrollment:  812

Study start: July 2005


Ages Eligible for Study:  18 Years   -   80 Years,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • Subject has been diagnosed with osteoarthritis of the hip or knee and requires NSAID to control pain.

Exclusion Criteria:

Location and Contact Information

Please refer to this study by identifier  NCT00139776

Valerie Marquino      212-733-4483

      Pfizer Investigational Site, Tustin,  California,  92780,  United States; Recruiting

      Pfizer Investigational Site, Laguna Hills,  California,  92653,  United States; Recruiting

      Pfizer Investigational Site, Paramount,  California,  90723,  United States; Recruiting

      Pfizer Investigational Site, Long Beach,  California,  90806,  United States; Recruiting

      Pfizer Investigational Site, Tampa,  Florida,  33614-7118,  United States; Recruiting

      Pfizer Investigational Site, Miami,  Florida,  33173,  United States; Recruiting

      Pfizer Investigational Site, Decatur,  Georgia,  30033,  United States; Recruiting

      Pfizer Investigational Site, Lexington,  Kentucky,  40509,  United States; Recruiting

      Pfizer Investigational Site, Madisonville,  Kentucky,  42431,  United States; Recruiting

      Pfizer Investigational Site, Baltimore,  Maryland,  21218,  United States; Recruiting

      Pfizer Investigational Site, Las Vegas,  Nevada,  89106,  United States; Recruiting

New York
      Pfizer Investigational Site, Manlius,  New York,  13104,  United States; Recruiting

      Pfizer Investigational Site, Great Neck,  New York,  11021,  United States; Recruiting

      Pfizer Investigational Site, Rochester,  New York,  14609,  United States; Recruiting

      Pfizer Investigational Site, Cleveland,  Ohio,  44122,  United States; Recruiting

      Pfizer Investigational Site, Zanesville,  Ohio,  43701,  United States; Recruiting

      Pfizer Investigational Site, Duncansville,  Pennsylvania,  16635-0909,  United States; Recruiting

      Pfizer Investigational Site, Johnstown,  Pennsylvania,  15904,  United States; Recruiting

      Pfizer Investigational Site, Beaver,  Pennsylvania,  15009,  United States; Recruiting

      Pfizer Investigational Site, Camp Hill,  Pennsylvania,  17011,  United States; Recruiting

      Pfizer Investigational Site, Johnson City,  Tennessee,  37601,  United States; Recruiting

      Pfizer Investigational Site, Dallas,  Texas,  75235,  United States; Recruiting

      Pfizer Investigational Site, Milwaukee,  Wisconsin,  53209,  United States; Recruiting

Study chairs or principal investigators

Pfizer Call Center,  Study Director,  Pfizer   

More Information

Study ID Numbers:  A3191173
Last Updated:  August 30, 2005
Record first received:  August 29, 2005 Identifier:  NCT00139776
Health Authority: United States: Food and Drug Administration processed this record on 2005-09-06


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us